Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy

Pletcher, Eric; Gleeson, Elizabeth M.; Labow, Daniel M.

doi:10.1016/j.suc.2020.02.009

Cited by 22 publications

(19 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore the choice of drugs under hyperthermic conditions is important because suitable hyperthermia can accelerate velocity of drug permeability into tumor tissue. So optimization of therapy regimen can increase cytotoxicity at the peritoneal lesions without an increase in systemic (especially bone marrow) toxicity [15,16]. Docetaxel is a semisynthetic taxane, which is widely used for NSCLC, breast cancer,gastric cancer,ovarian cancer,et al [17].…”

Section: Discussionmentioning

confidence: 99%

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

Jiang

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

Objective：The purpose of this study is to retrospectively observe the clinical efficacy and adverse reactions of docetaxel hyperthermic intraperitoneal chemotherapy (HIPEC) combined with endostar in treatment of malignant ascites. Methods：56 cases of malignant ascites admitted to Zhejiang Hospital from July 2019 and October 2020 had received no less than second-line chemotherapy. The observation group (n = 29) was treated with endostar 60mg d1,4,7 Q3W intraperitoneal injection combined with docetaxel 60mg/m2 d4 HIPEC Q3W for 2 cycles. The control group (n = 27) was just treated with docetaxel 60mg/m2 d1 HIPEC Q3W for 2 cycles. The general clinical data and qualitative data of the treatment results were processed by SPSS26.0 using χ2 test, and quantitative data were processed by t test. When P < 0.05, statistical data can be considered statistically significant.Results：There were significant differences between the observation group and the control group in objective response rate (ORR) (65.5% vs 37.0%，P=0.033)，in the improvement rate of KPS (48.3% vs 22.2%, P=0.042)，also in the median control time (57dvs 45d，P=0.027). The incidence of III to IV adverse reactions was low, and no treatment-related death was observed. There was no significant difference in the incidence of adverse reactions between the two groups.Conclusion：Endostar combined with docetaxel HIPEC has good clinical effect on malignant ascites and can improve patients’ quality of life, and the adverse reactions can be tolerated.

show abstract

Section: Discussionmentioning

confidence: 99%

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

Jiang

Chen

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…It is unclear if the IP administration, the heat, or the additional dose of chemotherapy is responsible for the benefit as all three interventions were utilized. These results are encouraging; however, further studies are needed before there is widespread adoption of this technique, which requires additional technical expertise [31,32].…”

Section: Surgical Managementmentioning

confidence: 95%

Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research

Wang

Wei

Liu

et al. 2020

JCM

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the most common histology of ovarian cancer defined as epithelial cancer derived from the ovaries, fallopian tubes, or primary peritoneum. It is the fifth most common cause of cancer-related death in women in the United States. Because of a lack of effective screening and non-specific symptoms, EOC is typically diagnosed at an advanced stage (FIGO stage III or IV) and approximately one third of patients have malignant ascites at initial presentation. The treatment of ovarian cancer consists of a combination of cytoreductive surgery and systemic chemotherapy. Despite the advances with new cytotoxic and targeted therapies, the five-year survival rate for all-stage EOC in the United States is 48.6%. Delivery of up-to-date guideline care and multidisciplinary team efforts are important drivers of overall survival. In this paper, we review our frontline management of EOC that relies on a multi-disciplinary approach drawing on clinical expertise and collaboration combined with community practice and cutting edge clinical and translational research. By optimizing partnerships through team medicine and clinical research, we combine our cancer center clinical expertise, community practice partnership, and clinical and translational research to understand the biology of this deadly disease, advance therapy and connect our patients with the optimal treatment that offers the best possible outcomes.

show abstract

“…Although primary peritoneal malignancies are rare, the peritoneum is a common site of metastases or peritoneal carcinomatosis (PC) for organs within the peritoneal cavity. Most commonly, PC arises from appendiceal, colorectal, ovarian, and gastric malignancies [ 1 , 2 , 3 ]. While less frequent, PC can also arise from gastrointestinal (GI) malignancies from other abdominal organs, including the small bowel, pancreas, gallbladder, and rarely from non-GI and extra-abdominal organs, such as breast, lung, and melanoma [ 1 , 2 , 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

“…Most commonly, PC arises from appendiceal, colorectal, ovarian, and gastric malignancies [ 1 , 2 , 3 ]. While less frequent, PC can also arise from gastrointestinal (GI) malignancies from other abdominal organs, including the small bowel, pancreas, gallbladder, and rarely from non-GI and extra-abdominal organs, such as breast, lung, and melanoma [ 1 , 2 , 3 , 4 ]. PC is so common with many GI malignancies that it is present at the time of diagnosis in approximately 5–10% of colorectal and 40–70% of appendiceal cancers [ 5 , 6 ].…”

Section: Introductionmentioning

confidence: 99%

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Harper

Kim

Pandalai

2022

JCM

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) is a poor prognostic factor for all malignancies. This extent of metastatic disease progression remains difficult to treat with systemic therapies due to poor peritoneal vascularization resulting in limited drug delivery and penetration into tissues. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are surgical interventions that directly target peritoneal tumors and have improved outcomes for PC resulting from appendiceal and colorectal cancer (CRC). Despite these radical therapies, long-term survival remains infrequent, and recurrence is common. The reasons for these outcomes are multifactorial and signal the need for the continued development of novel therapeutics, techniques, and approaches to improve outcomes for these patients. Here, we review landmark historical studies that serve as the foundation for current recommendations, recent discoveries, clinical trials, active research, and areas of future interest in CRS/HIPEC to treat PC originating from appendiceal and colorectal malignancies.

show abstract

Peritoneal Cancers and Hyperthermic Intraperitoneal Chemotherapy

Cited by 22 publications

References 104 publications

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

Docetaxel HIPEC Combined with Endostar versus Docetaxel HIPEC Alone in Treatment of Malignant Ascites：A Retrospective Study

Frontline Management of Epithelial Ovarian Cancer—Combining Clinical Expertise with Community Practice Collaboration and Cutting-Edge Research

Current Trends in Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Disease from Appendiceal and Colorectal Malignancies

Contact Info

Product

Resources

About